We showed previously that OX 1 orexin receptor stimulation produced a strong 3 H overflow response from [ 3 H]arachidonic acid (AA)-labeled cells. Here we addressed this issue with a novel set of tools and methods, to distinguish the enzyme pathways responsible for this response. CHO-K1 cells heterologously expressing human OX 1 receptors were used as a model system. By using selective pharmacological inhibitors, we showed that, in orexin-A-stimulated cells, the AA-derived radioactivity was released as two distinct components, i.e., free AA and the endocannabinoid 2-arachidonoyl glycerol (2-AG). Two orexin-activated enzymatic cascades are responsible for this response: cytosolic phospholipase A 2 (cPLA 2 ) and diacylglycerol lipase; the former cascade is responsible for part of the AA release, whereas the latter is responsible for all of the 2-AG release and part of the AA release. Essentially only diacylglycerol released by phospholipase C but not by phospholipase D was implicated as a substrate for 2-AG production, although both phospholipases were strongly activated. The 2-AG released acted as a potent paracrine messenger through cannabinoid CB 1 receptors in an artificial cell-cell communication assay that was developed. The cPLA 2 cascade, in contrast, was involved in the activation of orexin receptor-operated Ca 2ϩ influx. 2-AG was also released upon OX 1 receptor stimulation in recombinant HEK-293 and neuro-2a cells. The results directly show, for the first time, that orexin receptors are able to generate potent endocannabinoid signals in addition to arachidonic acid signals, which may explain the proposed orexincannabinoid interactions (e.g., in neurons).
Introduction
The peptide transmitters orexins/hypocretins, which act through G-protein-coupled OX 1 and OX 2 receptors, are involved in the regulation of homeostatic brain functions, especially wakefulness and sleep patterns and appetite (reviewed in Kukkonen et al., 2002; Scammell and Winrow, 2011) . Orexin receptor expression and signaling are also found in the periphery of the body, but the physiological significance of this is not known. The molecular mechanisms of orexin receptor signaling are very diverse (reviewed in Kukkonen and Åkerman, 2005) . Especially prominent seems to be coupling to the production of messengers through phospholipase action (Johansson et al., 2008; Turunen et al., 2010a; Jä ntti et al., 2012) .
Endocannabinoids are phospholipid-derived messengers that contain arachidonic acid (AA). The most well established endocannabinoids are 2-arachidonoylglycerol (2-AG) and anandamide (N-arachidonoyl-ethanolamine) (reviewed in Kano et al., 2009) . Endocannabinoids act through G-proteincoupled CB 1 and CB 2 receptors; the CB 1 receptor is ex-pressed in central neurons. In addition to the receptors, the endocannabinoid system includes the enzymes that produce and metabolize endocannabinoids. Endocannabinoids are generally thought to be produced on demand and not stored in membrane vesicles like traditional neurotransmitters. Endocannabinoid signaling has been a subject of much interest from both the basic physiological perspective and the medical one. In the central nervous system, endocannabinoids are involved in the regulation of, e.g., appetite, nociception, memory, reward, and mood (reviewed in Kano et al., 2009) . On the synaptic level, endocannabinoids engage in retrograde transmission, in which postsynaptically produced endocannabinoids act on the inhibitory, presynaptic CB 1 receptors. This function may also act in homosynaptic feedback, but the assumed major function is heterosynaptic. Cannabinoid receptors couple to G-proteins in the G i family, and the presynaptic inhibition is likely to occur through G␤␥-mediated inhibition of voltage-gated Ca 2ϩ channels and inward rectifier K ϩ channels (reviewed in Howlett, 2005; Kano et al., 2009 ). There is much circumstantial evidence for interactions between orexinergic and cannabinoidergic systems. These systems show significant overlap on the gross neuroanatomical level, especially in particular nuclei of the hypothalamus. However, the possibility of interactions at the cellular level has not been verified for most nuclei. More-direct evidence is scarce. In the lateral hypothalamus, exogenous CB 1 receptor stimulation inhibits orexinergic neurons by reducing the excitatory drive on them (Huang et al., 2007) . In contrast, CB 1 receptor block attenuates orexin-A-induced feeding (Crespo et al., 2008) . It was proposed that CB 1 and OX 1 receptors form heteromeric complexes, which may enhance orexin signaling (Hilairet et al., 2003; Ellis et al., 2006; Ward et al., 2011) .
We showed previously that OX 1 orexin receptor activation strongly stimulates 3 H overflow from [ 3 H]AA-labeled cells (Turunen et al., 2010a) . The full sensitivity of the response to the reputed phospholipase A 2 (PLA 2 ) inhibitor methyl arachidonyl fluorophosphonate (MAFP), in addition to partial sensitivity to inhibitors of other enzymes and intracellular signal pathways (Turunen et al., 2010a) , suggests that this effect is mediated by PLA 2 enzymes. Although MAFP is very commonly used as a PLA 2 inhibitor, it is an analog of AA and is able to inhibit a number of serine hydrolases that hydrolyze ester-or amide-bound AA (De Petrocellis et al., 1997; Deutsch et al., 1997; Dinh et al., 2002; Savinainen et al., 2010) . Therefore, does the 3 H overflow observed take place solely through PLA 2 , and which isoform is involved?
Another question left open is whether the 3 H overflow is composed only of AA or whether other water-soluble and secreted metabolites are involved. In the current study, we set out to resolve these questions. The results demonstrate that both free AA and AA incorporated into the endocannabinoid 2-AG are released upon orexin receptor stimulation. Both AA and 2-AG are shown to have signaling roles of their own.
Materials and Methods

Drugs.
Human orexin-A and -B were obtained from NeoMPS (Strasbourg, France). 1-(2,4-Dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide (AM-251), [4-[5-methoxy- -[2-[4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl Scott et al., 2009) , N-cyclohexanecarbonylpentadecylamine (CCPA) (compound 17 in Tsuboi et al., 2004) , 1,1,1,2,2-pentafluoro-7-phenyl-heptan-3-one (FKGK11) (compound 10a in Baskakis et al., 2008), 3-(1,1Ј-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6- Seno et al., 2001), and [3-(3-carbamoylphenyl) phenyl] Ncyclohexylcarbamate (URB597) were obtained from Cayman Europe (Tallinn, Estonia). 1,6-Bis(cyclohexyloximinocarbonylamino) hexane 
, and 1-[6-([(17b)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino)hexyl]-1H-pyrrole-2,5-dione (U-73122) were obtained from Tocris Bioscience (Bristol, UK), fura-2 acetoxymethyl ester from Invitrogen (Carlsbad, CA), and [5, 6,8,9,11,12,14,15- 3 H]AA, [1-14 C]AA, and [9,10-3 H]oleic acid from PerkinElmer Life and Analytical Sciences (Waltham, MA). Forskolin, probenecid [p-(dipropylsulfamoyl) benzoic acid], and 3-isobutyl-1-methylxanthine (IBMX) were obtained from SigmaAldrich (St. Louis, MO).
Cell Culture. CHO-hOX 1 cells expressing ϳ500 fmol/mg of protein levels of high-affinity human OX 1 receptors (as determined from high-affinity 125 I-orexin-A binding (P. M. Turunen and J. P. Kukkonen, unpublished data) were described previously, as were their culture conditions (Lund et al., 2000; Turunen et al., 2010a) . CHO-hCB 1 cells expressing human CB 1a receptors (Grimsey et al., 2010) were a kind gift from Dr. Michelle Glass (University of Auckland, Auckland, New Zealand) via Drs. Jarmo Laitinen and Juha Savinainen (University of Eastern Finland, Kuopio, Finland); these cells were propagated under the same conditions as CHO-hOX1 cells except that 0.25 mg/ml phleomycin (Zeocin; Invitrogen) was included. Neuro-2a-hOX 1 , PC12-hOX 1 , and wildtype HEK-293 cells were propagated as described previously Putula and Kukkonen, 2012) ]oleic acid-labeled cells and for the 2-AG reporter assays, the CHOhOX 1 cells were cultivated on 24-well plates (well bottom area, 1.77 cm 2 ; Greiner Bio-One GmbH, Frickenhausen, Germany) coated with polyethylenimine (25 g/ml for 1 h at 37°C; SigmaAldrich); for Ca 2ϩ imaging, the cells were cultivated on polyethylenimine-coated, circular, glass coverslips (diameter, 13 mm; Menzel-Glä ser, Braunschweig, Germany). For the thin-layer chromatography (TLC) assays, the cells were cultured on six-well plates (bottom area, 9.6 cm 2 ; Greiner Bio-One). For cAMP measurements (direct CB 1 receptor assay or 2-AG reporter assay), CHO-hCB 1 cells were cultured on plastic culture dishes (bottom area, 56 cm 2 ; Greiner Bio-One). HEK-293 cells were transiently transfected with hOX 1 receptor cDNA by using Fugene HD (Roche Diagnostics GmbH, Mannheim, Germany), as described previously (Turunen et al., 2010a) . CHO-hOX 1 cells were plated on 24-well plates (20,000 cells per well) and left to grow for 24 h. The wells were precoated with polyethylenimine, which very much reduced cell detachment during the washes. Then, 0.1 Ci of [ 3 H]AA (or 0.2 Ci of [ 3 H]oleic acid, to compensate for the lower release levels and lower 3 H content) was added to each well, and the cells were cultured for another 20 h. The incubation medium was removed, the cells were washed twice with HEPES-buffered medium (HBM) (137 mM NaCl, Orexin-Induced Arachidonic Acid and Endocannabinoid Release 5 mM KCl, 1 mM CaCl 2 , 1.2 mM MgCl 2 , 0.44 mM KH 2 PO 4 , 4.2 mM NaHCO 3 , 10 mM glucose, and 20 mM HEPES, adjusted to pH 7.4 with NaOH) supplemented with 2.4 mg/ml stripped bovine serum albumin (S-BSA) (Turunen et al., 2010b) , and the cells were left in HBM with S-BSA at 37°C. The cells were immediately stimulated with orexin-A or thapsigargin for 7 min, after which 200 l of the total volume of 250 l in each well was transferred to Eppendorf tubes (VWR International, Radnor, PA) on ice. The samples were centrifuged (16,000g for 1.5 min at 4°C), 100 l of the medium was transferred to a scintillation tube, scintillation cocktail (HiSafe 3; PerkinElmer Life and Analytical Sciences) was added, and the radioactivity was measured with a Wallac 1414 liquid scintillation counter (PerkinElmer Life and Analytical Sciences). It should be noted that total radioactivity released in the supernatant from the 3 H-preloaded cells was measured in this assay without any separation with respect to molecular species.
In some cases, orexin stimulation was preceded by some inhibitor preincubation. In such cases, the inhibitor used was added to the cells after one wash with HBM plus S-BSA, and the cells were preincubated for 30 min in HBM in the absence of S-BSA. HBM plus 10ϫ S-BSA was added to a final concentration of S-BSA of 2.4 mg/ml for the last 5 min, to chelate the radioactivity leaked during this period. The incubation solution was removed, fresh HBM plus S-BSA with the inhibitor was added, and the cells were stimulated immediately with orexin-A for 7 min. The control cells were treated in the same way. The procedure effectively removed the radioactivity leaked during the preincubation period, and the S-BSA did not interfere with inhibitor entry into the cells.
Lipid Extraction and TLC. 14 C]AA loading medium was removed, and the cells were washed twice with HBM plus S-BSA (2.4 mg/ml) and stimulated with orexin-A for 7 min. Supernatants from the cells were rapidly removed and centrifuged (16,000g for 2 min at 4°C) to remove detached cells. The lipids were extracted from the supernatant with a slight modification of the method described by Bligh and Dyer (1959) . Briefly, 800 l of the total supernatant (1000 l) was transferred to a Kimax tube (Kimble Glass, Inc., Vineland, NJ), 2 ml of methanol was added, followed by 1 ml of chloroform, and the tubes were shaken thoroughly. After the addition of 1 ml of water and 1 ml of chloroform, the tubes were shaken again and centrifuged (500g for 5 min at room temperature). The lower phase was collected and dried under a stream of N 2 . The dried lipids were dissolved in chloroform, and the samples were applied to TLC plates (Silicagel 60; Merck, Darmstadt, Germany), which were dried at 110°C for 1 h. The plates underwent development with ethyl acetate/ methanol (90:10) (Glass et al., 2005) in a chromatography tank lined with filter paper. Nonlabeled lipid standards were included on each TLC plate, either in separate lanes or together with the samples; the movement of the lipids of interest (2-AG and AA) in the samples was not affected by the presence of the standards. The average retardation factor values for AA and 2-AG were 0.58 Ϯ 0.01 and 0.67 Ϯ 0.01, respectively. TLC data were quantitated both through imaging plate analysis and through scraping and scintillation counting; the two methods yielded comparable results (Jä ntti et al., 2012) . For this reason, only the results from the imaging plate analysis are presented. After development, the plates were vacuum-dried and an imaging plate (BAS-MS; Fujifilm, Tokyo, Japan) was exposed overnight. The imaging plate was scanned with a Fujifilm FLA 5100 scanner, and the band areas and intensities were measured with ImageJ (http://rsbweb.nih.gov/ij). The plate background was subtracted from the band intensities.
2-AG Reporter Assay and cAMP Measurements. 2-AG release from CHO-hOX 1 cells upon orexin receptor stimulation was detected and quantitated by using CHO-hCB 1 cells as detector cells; the assay is conceptually reminiscent of, for instance, a nitric oxide production assay (Hu and el-Fakahany, 1993) . CHOhCB 1 cells on cell culture dishes were prelabeled with 5 Ci/ml [ 3 H]adenine in culture medium for 2 h, after which the cells were washed with phosphate-buffered saline and detached with phosphate-buffered saline plus 0.2% (w/v) EDTA. The cells were centrifuged, resuspended in HBM containing 500 M IBMX (a cyclic nucleotide phosphodiesterase inhibitor), and dispensed on top of CHO-hOX 1 cells growing on 24-well plates that had been washed with HBM. Different densities of CHO-hCB 1 cells were tested, but we finally chose a density of 150,000 cells per well. The plates were gently centrifuged (100g for 3 min at room temperature) to sediment CHO-hCB 1 cells on top of CHO-hOX 1 cells in HBM. The cells were allowed to rest at 37°C for 10 min, after which they were stimulated for 7 min with orexin-A or HU-210. The final volume in each well was 250 l. When inhibitors were included, these cells (and the control cells) were preincubated with the inhibitor or vehicle for 10 min (SB-334867 and AM-251) or 30 min (THL) before orexin stimulation. The reactions were interrupted through rapid removal of the medium, addition of 300 l of ice-cold 0.33 M perchloric acid, and freezing. The insoluble fragments of the thawed samples were centrifuged (1100g for 10 min at room temperature), and the 3 H]adenine, the radioactivity isolated was derived from those cells alone.
CHO-hCB 1 cells were also subjected to cAMP measurements in the absence of CHO-hOX 1 cells. The assay was similar to that described above, except that the detached cells were preincubated for 10 min in HBM plus IBMX (with inhibitors, if they were used) and then dispensed on 96-well plates (10 5 cells per well) where the stimulants (orexin-A, HU-210, and 2-AG) were already present. The final volume was 150 l per well. On the plates, 0.5 mg/ml S-BSA was included, because this helped to maintain 2-AG in solution (Savinainen et al., 2003) . After 10 min of stimulation, the reactions were interrupted through rapid centrifugation (1100g for 3 min at 4°C) of the cells, removal of the medium, addition of 150 l of ice-cold 0.33 M perchloric acid, and freezing. The samples were then treated as described above. Ca 2؉ Measurements. Cells plated on polyethylenimine-coated glass coverslips were loaded for 20 min at 37°C with 4 M fura-2 Fig. 1 . Orexin-A-stimulated acetoxymethyl ester in HBM containing 1 mM probenecid, rinsed once, and used immediately. Ca 2ϩ measurements were performed at 35°C with a Nikon TE2000 fluorescence microscope (20ϫ/0.75 air objective) and an Andor iXon 885 electron-multiplying chargecoupled device camera under the control of Nikon NIS Elements AR software with 6D extension (Nikon, Tokyo, Japan). For Ca 2ϩ imaging, the cells were excited with alternating 340-and 380-nm light (Sutter DG4 Plus wavelength switcher; Sutter Instrument Company, Novato, CA), and the emitted light was collected through a 400-nm dichroic mirror and a 450-nm long-pass filter. Additions were made with constant perfusion (HBM with probenecid). When the inhibitors THL and pyrrophenone were tested, the cells were pretreated with the compounds for 20 min and the compounds were included in the perfusion medium throughout the experiment. Regions of interest were defined with NIS software, and the data were extracted to Microsoft Excel (Microsoft, Redmond, WA) for observation and quantitation. More than 30 cells were measured in each experiment, and each experiment was repeated four times or more.
Data Analysis. All data are presented as mean Ϯ S.E.M.; N refers to the number of batches of cells. Each experiment was performed at least three times. The AA-release experiments were performed with six data points in parallel, imaging with 30 or more, cAMP measurements with three or four, and TLC with two. Student's two-tailed t test with Bonferroni correction was used for all pairwise comparisons except in Fig. 8 , where, because of the nonparametric nature of cell counting, the 2 test also was used . Microsoft Excel was used for nonlinear curve-fitting for the determination of EC 50 values. The effects of inhibitors on orexin-stimulated AA and 2-AG release were calculated from the values by using a formula that compensated for the possible effects of the inhibitors on basal release, i.e., release [percentage of A, the orexin response is inhibited by the PLC inhibitor U-73122 but not by the PLD1 inhibitor CAY10593. B and C, the orexin response is partially inhibited by the DAGL inhibitors THL and RHC-80267 (B) and the cPLA 2 ␣/ inhibitor pyrrophenone (C). D, the combination of THL and pyrrophenone produces full inhibition of the orexin response. E, the response to 1 M thapsigargin is nearly fully blocked by pyrrophenone alone. The data were normalized so that each control response (basal, 3 nM orexin-A, and 100 nM orexin-A) amounts to 100% (see Materials and Methods) . Some differences in the inhibitory efficacy can be seen in B, C, and D, because only experiments in which all of the inhibitors were tested were included in the analysis in D, to allow direct comparison of the efficacy of THL and pyrrophenone. Comparisons are to the corresponding control (ctrl) values (N ϭ 3-7); ns, not significant (p Ͼ 0.05); ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001.
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Results
Orexin Receptor Stimulation Induces [
3 H]AA-Derived 3 H Overflow through Distinct Cytosolic PLA 2 and Diacylglycerol Lipase Cascades. Our previous studies showed strong release of radioactivity from [ 3 H]AA-labeled CHO-hOX 1 cells upon OX 1 receptor stimulation (Fig. 1 ), but the enzymes responsible for this could not be resolved because of the low selectivity of the inhibitors available (Turunen et al., 2010a) . We showed that OX 1 receptors also potently activate both phospholipase C (PLC) and phospholipase D (PLD) cascades (Johansson et al., 2008; Jä ntti et al., 2012) , producing diacylglycerol (DAG) and phosphatidic acid (PA), respectively. Both of these compounds could act as substrates for AA release, through the DAG lipase (DAGL)-monoacylglycerol lipase (MAGL) and PA-PLA 2 cascades, respectively, and PA can also be hydrolyzed to DAG by PA phosphohydrolase (reviewed in Kukkonen, 2011) . Only PLD1 and not PLD2 is activated by orexin receptor stimulation in CHO cells, and this isoform can be fully inhibited by CAY10593 (Jä ntti et al., 2012) . CAY10593 produced very weak (10-20%) inhibition of 3 H overflow ( Fig. 2A ). In contrast, the PLC inhibitor U-73122 produced full inhibition ( Fig. 2A) .
THL is used as a pancreatic triglyceride lipase inhibitor, but it is an even more-potent inhibitor of some related enzymes, including DAGL (Lee et al., 1995; Bisogno et al., 2003) , and it can be used at 1 M as a relatively selective DAGL inhibitor (Bisogno et al., 2006) (V. Di Marzo, personal communication) . THL produced significant inhibition of the orexin response even at 1 M (Fig. 2B) . RHC-80267, a lesspotent DAGL inhibitor, showed a similar trend of inhibition (Fig. 2B) .
Selective inhibitors for particular PLA 2 isoforms have been produced during the past 10 years. The most well characterized (e.g., for selectivity) of these are different pyrrolidine inhibitors for cytosolic PLA 2 (cPLA 2 ) ␣ (Seno et al., 2000 (Seno et al., , 2001 . A commercially available inhibitor of this type, pyrrophenone (Seno et al., 2001) , at 1 M produced significant inhibition of the orexin response (Fig. 2C) . Interestingly, the inhibition profile was the opposite of that for THL; whereas THL apparently produced weaker inhibition with 3 nM orexin-A and stronger inhibition with 100 nM, pyrrophenone was stronger with 3 nM orexin-A. We hypothesized that DAGL and cPLA 2 might represent two components of the orexin-stimulated 3 H overflow from [ 3 H]AA-labeled cells. The combination of THL and pyrrophenone produced full inhibition of the orexin-A response (Fig. 2D) . In contrast, the response to thapsigargin showed no sensitivity to THL but was almost fully inhibited by pyrrophenone alone (Fig. 2E ), in agreement with Ca 2ϩ activation of cPLA 2 (reviewed in Ghosh et al., 2006) . Although Ca 2ϩ level elevation should also stimulate DAGL (Bisogno et al., 2003) , Ca 2ϩ level elevation (at least when triggered by thapsigargin or ionomycin) is a poor stimulant of PLD and an even poorer stimulant of PLC in CHO cells (Lund et al., 2000; Johansson et al., 2007; Jä ntti et al., 2012) ; therefore, in the absence of DAG production, there was no DAGL activity.
The orexin response appears to rely on two different components. The relative contributions of the components might become clearer with normalized raw data instead of inhibi- Fig. 2D ; N ϭ 5). The significances are the same as in Fig. 2D . B, representative experiment. The data were normalized so that each basal level is 0% and the maximal response to 100 nM orexin-A in the absence of inhibitors is 100% [response ϭ (orexin inhibitor Ϫ basal inhibitor )/ (orexin 100 nM-ctrl Ϫ basal ctrl ) ϫ 100%]. ctrl, control; non-inhibited components together, procedure in which the orexin responses remaining after THL and pyrrophenone were added together. tion data (Fig. 3A) . The same finding could also be seen with more complete concentration-response curves (Fig. 3B) . The patterns of inhibition with THL and pyrrophenone were essentially not overlapping (Fig. 3) . In the analyses of the concentration-response data, the control pEC 50 value was 8.7 Ϯ 0.1 and the pEC 50 values after pyrrophenone (putative DAGL component) and THL (putative cPLA 2 component) treatment were 8.4 Ϯ 0.1 and 9.3 Ϯ 0.1, respectively (N ϭ 3-5). Therefore, the putative cPLA 2 component would be activated with significantly higher potency (see Discussion).
We (Fig. 4). [
3 H]Oleic acid is likely to end up in the sn1 position, which is not hydrolyzed by cPLA 2 . Even if some oleic acid would be found in the sn2 position, cPLA 2 ␣ (in contrast to other PLA 2 isoforms, including cPLA 2 ) is rather specific for AA in the sn2 position (reviewed in Ghosh et al., 2006 Ghosh et al., , 2007 . Endocannabinoid-Hydrolyzing Enzymes, HormoneSensitive Lipase, and Intracellular PLA 2 in OrexinInduced, AA-Derived 3 H Overflow. DAG lipases are thought to show sn1 selectivity (3-8-fold in vitro) (Bisogno et al., 2003) ; therefore, DAGL might be thought to be unlikely to release AA from its usual sn2 position. DAGL, however, works as a "gatekeeper" for MAGL, because no monoacylglycerol should be produced in the absence of DAGL activity. We tested a selective MAGL inhibitor, JZL184 (Long et al., 2009 ). JZL184 (10 M) produced weak but significant inhibition (20 Ϯ 12% with 3 nM orexin-A, p Ͻ 0.01; 11 Ϯ 10% with 100 nM orexin-A, p Ͻ 0.05) (Supplemental Fig. 1 ). We similarly tested inhibitors of fatty acid amide-type endocannabinoid-hydrolyzing enzymes, URB597 (100 nM; fatty acid (N ϭ 8) . B, inhibitory actions of THL. C, inhibitory actions of pyrrophenone. D, combined effects of THL and pyrrophenone on AA and 2-AG release upon OX 1 receptor stimulation. E, summarized data for inhibition of AA release (N ϭ 3-5). F, summarized data for inhibition of 2-AG release (N ϭ 3-5). The data in the bar graphs were normalized to the AA-release response to 100 nM orexin-A (100%). Comparisons are to the corresponding control (ctrl) values; ns, not significant (p Ͼ 0.05); ‫,ء‬ p Ͻ 0.05; ‫,ءء‬ p Ͻ 0.01; ‫,ءءء‬ p Ͻ 0.001.
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at ASPET Journals on June 25, 2017 molpharm.aspetjournals.org amide hydrolase [FAAH] inhibitor) and CCPA (100 M; Nacylethanolamine-hydrolyzing acid amidase/acidic palmitoyl ethanolamidase inhibitor) (Kathuria et al., 2003; Tsuboi et al., 2004; Long et al., 2009 Fig. 1) . Similarly, the hormone-sensitive lipase/FAAH/MAGL inhibitor CAY10499 (30 M) and the intracellular PLA 2 (iPLA 2 ) inhibitor FKGK11 (10 M) (Baskakis et al., 2008; Muccioli et al., 2008; Minkkilä et al., 2009) were incapable of inhibiting the orexin response (Supplemental Fig. 1 The results showed that the radioactivity released upon orexin receptor stimulation was found both in free AA and in the endocannabinoid 2-AG (Fig. 5A) ; AA was released with significantly higher potency by cPLA 2 (AA release in the presence of THL) than was 2-AG by DAGL (pEC 50 values of 9.8 Ϯ 0.1 and 8.3 Ϯ 0.1, respectively; N ϭ 3-9) (Fig. 6) . THL fully blocked orexin-stimulated 2-AG release but only partly reduced AA release (Figs. 5, B , E, and F, and 6). In contrast, pyrrophenone inhibited only AA and not 2-AG release (Fig. 5, C , E, and F). Inclusion of both THL and pyrrophenone fully inhibited orexin-stimulated release of both free AA and 2-AG (Fig. 5, D , E, and F).
Other OX 1 receptor-expressing cells showed distinct responses to orexin-A stimulation. Neuro-2a and HEK-293 cells showed strong 2-AG release with 100 nM orexin-A (Supplemental Fig. 2 ). In addition, AA release was seen; orexin stimulation of 2-AG and AA release was eliminated by THL (data not shown), which suggests that AA was released through 2-AG breakdown and not through PLA 2 action on phospholipids. PC12 cells showed high basal levels of AA release, with no apparent stimulation with orexin-A, and no 2-AG release (Supplemental Fig. 2) .
Orexin Receptor Activation Is Able to Induce Strong Paracrine Signaling to Cannabinoid Receptors through 2-AG. 2-AG is a potent endogenous ligand for cannabinoid receptors (reviewed in Di Kano et al., 2009 ). Therefore, we tested whether 2-AG released upon orexin receptor signaling was able to activate cannabinoid receptors. For this, we designed a cell-cell communication assay between CHO-hOX 1 and CHO-hCB 1 cells, as described in Materials and Methods. CHO-hCB 1 cells were plated on top of the CHO-hOX 1 cell culture, CHO-hOX 1 cells were stimulated with orexin-A, and 2-AG production was detected as selective inhibition of adenylyl cyclase in CHO-hCB 1 cells. Orexin-A in this assay caused strong potent inhibition of adenylyl cyclase activity in CHO-hCB 1 cells, although the efficacy was somewhat lower than that of direct stimulation with the CB 1 agonist HU-210 (Fig. 7, A and B) . The response to orexin-A was fully inhibited by the OX 1 receptor antagonist SB-334867, by THL, and by the CB 1 receptor antagonist/inverse agonist AM-251 (Fig. 7A) , which indicated that inhibition of forskolin-stimulated adenylyl cyclase activity in CHO-hCB 1 cells by orexin-A was mediated through the cascade of orexin-A 3 OX 1 (on CHOhOX 1 cells) 33 2-AG (by DAGL in CHO-hOX 1 cells) 3 CB 1 (on CHO-hCB 1 cells). AM-251 but neither THL nor SB-334867 enhanced the forskolin-stimulated cAMP production (Fig. 7A) , which suggests that CB 1 receptors show some constitutive activity. SB-334867 alone weakly inhibited the forskolin response (Fig. 7A) , which suggests that SB-334867 shows some weak partial agonist activity at OX 1 receptors, in line with some previous observations (Bengtsson et al., 2007 ) (J. Putula and J. P. Kukkonen, unpublished observations). AM-251 at 10 M strongly but incompletely inhibited the response to 1 M HU-210 (data not shown; see also below).
In CHO-hCB 1 cells alone, exogenous 2-AG was nearly as efficacious as HU-210 as a CB 1 receptor activator (Fig. 7, C  and D) . AM-251 increased adenylyl cyclase activity, compared with forskolin alone (Fig. 7C) , as also seen in the reporter assay (Fig. 7A) , and fully blocked the response to 2-AG (Fig. 7C) . In contrast, the response to 1 M HU-210 was not fully blocked (data not shown), similar to the reporter assay results, which likely reflects the fact that the affinity/ potency of HU-210 is too high (ϳ100-1000-fold higher than that of 2-AG) to be fully blocked at this concentration by 10 M AM-251.
To obtain an estimate of the 2-AG levels reached upon orexin receptor stimulation, we measured the potency of exogenous 2-AG to activate CB 1 receptors in CHO-hCB 1 cells (Fig. 7D) . With the use of these data (maximal inhibition ϭ 86 Ϯ 3%, pEC 50 ϭ 7.40 Ϯ 0.03, n H ϭ 1.1 Ϯ 0.2; N ϭ 5) as a standard curve for calculation of 2-AG levels from data on adenylyl cyclase inhibition by orexin-A in the reporter assay (maximal inhibition ϭ 60 Ϯ 3%, pEC 50 ϭ 9.1 Ϯ 0.1, n H ϭ 1.5 Ϯ 0.1; N ϭ 4), the average orexin-A-induced increase in 2-AG levels sensed by the CHO-hCB 1 cells may be ϳ87 nM and the pEC 50 for orexin-A for 2-AG production ϳ8.8. cPLA 2 but Not DAGL Activity Is Pivotal for OX 1 Receptor Activation of Receptor-Operated Ca 2؉ Influx. We showed previously that MAFP could strongly inhibit OX 1 receptor-operated Ca 2ϩ influx (Turunen et al., 2010a) , which is central for orexin receptor-mediated Ca 2ϩ level increases because it also drives PLC activity at low orexin concentrations (Lund et al., 2000; Johansson et al., 2007) . Because MAFP is a potent inhibitor of both the cPLA 2 and DAGL pathways, we tested selective inhibitors of these pathways, i.e., pyrrophenone and THL, in Ca 2ϩ imaging assays. Pyrrophenone produced equally strong inhibition (Fig. 8, A and B) , compared with MAFP (data not shown) (Turunen et al., 2010a) , whereas THL was incapable of inhibiting the Ca 2ϩ influx response (Fig. 8, A and C) , which clearly indicates that the cPLA 2 pathway is involved in orexin receptor-operated Ca 2ϩ influx. Inclusion of both pyrrophenone and THL did not produce stronger inhibition than that observed with pyrrophenone alone (Fig. 8, A, B, and D) .
Discussion
We targeted the [ 3 H]AA-derived 3 H overflow by using a number of established or novel inhibitors of lipases and amidases that are capable of releasing AA. Most importantly, THL, an inhibitor of DAGL, and pyrrophenone, an inhibitor of cPLA 2 ␣ and - (Seno et al., 2001; Ghomashchi et al., 2010) produced complementary inhibition, together reaching full inhibition. THL was selected as the DAGL inhibitor for detailed investigations because of its greater potency, efficacy, and stability and its likely greater selectivity, compared with RHC-80267. The pharmacological selectivity of the inhibitors in CHO cells was confirmed with respect to thapsigargininduced 3 H overflow from [ 3 H]AA-labeled cells (fully inhibited by pyrrophenone) and orexin-A-induced 3 H overflow from [
3 H]oleic acid-labeled cells (fully inhibited by THL). The conclusive evidence was obtained through TLC separation of [ 14 C]AA-labeled lipid species, which showed that the apparent orexin-A-induced AA overflow was composed of free AA as well as 2-AG. 2-AG release was fully dependent on DAGL (inhibited by THL), whereas the free AA component was dependent on both the cPLA 2 and DAGL pathways (additively inhibited by pyrrophenone and THL, respectively). The results are summarized in Fig. 9 . The DAGL pathway is likely to follow from PLC activity, as suggested by both inhibition by the PLC inhibitor U-73122 and only minor inhibition by the PLD inhibitor CAY10593. 2-AG production closely mirrors PLC activity, as judged from total inositol phosphate release and DAG generation in the presence of (Johansson et al., 2008) . It is unclear, however, whether DAGL in general passively follows PLC activity or is actively regulated by, e.g., Ca 2ϩ level elevation (Bisogno et al., 2003) or phosphorylation. MAGL or another component with similar activity (Long et al., 2009) , degrading 2-AG to glycerol and AA, is likely to be responsible for the inhibition of free AA release by THL. We also used a number of other inhibitors of enzymes with possible AA-releasing capacity, including the MAGL inhibitor JZL184, the FAAH inhibitor URB597, the MAGL/FAAH/hormone-sensitive lipase inhibitor CAY10499, the iPLA 2 inhibitor FKGK11, and the N-acylethanolamine-hydrolyzing acid amidase/acidic palmitoyl ethanolamidase inhibitor CCPA. Whereas JZL184, URB597, and CAY10499 are rather well characterized, FKGK11 and CCPA are not (they have been used in only a few studies), and it was difficult to estimate their effective concentrations. However, none of the inhibitors except JZL184 produced any inhibition, which is logical in light of the studies clearly indicating the involvement of cPLA 2 and DAGL only. It is unclear why JZL184 produced a small but significant amount of inhibition of 3 H overflow. At the concentration used, CAY10499 also is an effective inhibitor of MAGL (Muccioli et al., 2008; Minkkilä et al., 2009) , but it did not show any inhibition here; therefore, it is possible that the inhibition seen with JZL184 is attributable to an effect on some target other than MAGL.
cPLA 2 is activated with high potency by orexin receptors and may be a potent physiological signal. In the current study, we could verify that it was cPLA 2 and not DAGL signaling that was required for the activity of the receptoroperated Ca 2ϩ influx pathway. Our results do not reveal, however, whether it is AA or some other polyunsaturated fatty acid, the other product of cPLA 2 activity, lysophosphatidylcholine, or some metabolite of those compounds that mediates the response. All of those metabolites could be active at transient receptor potential or ARC channels (reviewed in Kukkonen, 2011) . cPLA 2 enzymes are known to be sensitive to Ca 2ϩ level increases. The PLC inhibitor U-73122 fully inhibited 3 H overflow from [ 3 H]AA-labeled cells, which suggested that PLC activity was required for both cPLA 2 and DAGL pathways. U-73122 is known to be toxic to CHO cells (Taylor and Broad, 1998; Lund et al., 2000) and it can fully block orexin receptor-mediated Ca 2ϩ influx (Smart et al., 1999) , although inositol-1,4,5-trisphosphate-dependent Ca 2ϩ influx is not involved in this response . In addition, cPLA 2 activity occurs with a higher potency than PLC or DAGL activity (see below). Therefore, we doubt the conclusion regarding involvement of PLC in cPLA 2 activation. Unfortunately, there are no other effective (and nontoxic) PLC inhibitors available (at least for CHO cells), and the activation mechanism for cPLA 2 thus remains unclear. However, we know that the increase in Ca 2ϩ levels (likely through influx) induced by thapsigargin is a potent stimulator of cPLA 2 in these cells (present study) (Turunen et al., 2010a) (Turunen et al., 2010a) . It is possible that there is a feed-forward cycle in orexin receptor signaling involving cPLA 2 and receptor-operated Ca 2ϩ influx. However, additional experiments are required to resolve this and alternative options.
The potency of orexin-A for cPLA 2 and DAGL activation was determined in several ways. 2-AG would be released by DAGL with pEC 50 values of 8.4 ( 3 H overflow in the presence of pyrrophenone), 8.3 (TLC assay), and 8.8 (2-AG release reporter assay). AA would be released by cPLA 2 with pEC 50 values of 9.3 ( 3 H overflow in the presence of THL) and 9.8 (TLC assay in the presence of THL). Some of the variation may depend on the resolution of the assays; for example, TLC separation showed much less variation and thus greater sensitivity than the 3 H overflow assay. cPLA 2 was clearly activated with significantly greater potency than DAGL in CHO cells. In the other cell types examined, the situation was different. It is interesting that, in all of these cell types, orexin receptors couple to PLC Putula and Kukkonen, 2012) ; therefore, the differences in 2-AG release might be related to another component, such as lack of DAGL or the putative 2-AG transporter or effective alternative metabolism of DAG or degradation of 2-AG.
Our previous results obtained with the reputed iPLA 2 inhibitor bromoenol lactone suggested partial involvement of iPLA 2 in the orexin-stimulated 3 H overflow (Turunen et al., 2010a) . Bromoenol lactone is known to act on different serine hydrolases (reviewed in Balsinde and Balboa, 2005) , forming a soluble, reactive, molecular species that can form cysteine adducts with bystander proteins (Song et al., 2006) . We are convinced that the previous results obtained with bromoenol lactone do not indicate the involvement of iPLA 2 but represent a result of nonspecific interactions of this inhibitor. This is supported by the fact that a novel iPLA 2 inhibitor, FKGK11, did not inhibit 3 H overflow. Orexin-endocannabinoid interactions have been investigated in a few studies. CB 1 receptor mRNA and preproorexin mRNA are expressed in close apposition in the lateral hypothalamus, in part in the same cells (Cota et al., 2003) . The physiological functions of orexins and endocannabinoids in appetite stimulation are similar, and leptin, a satiety messenger and negative regulator of orexinergic neurons (Hå-kansson et al., 1999; López et al., 2000) , is also a negative regulator of endocannabinoid levels (Di Marzo et al., 2001 ). These systems may be involved in the same pathways. A study indicated endocannabinoid involvement in orexin-mediated stimulation of appetite (Crespo et al., 2008) , and similar findings are indicated for the analgesic action of orexin-A (Ho et al., 2011) . In contrast, endocannabinoids inhibit orexin signaling in the lateral hypothalamus by reducing the excitatory glutamatergic drive to orexinergic neurons (Huang et al., 2007) . Endocannabinoids may have different functions in the lateral hypothalamus and in upstream regulatory centers of orexinergic neurons; whereas endocannabinoids in the lateral hypothalamus may suppress orexinergic neurons (Huang et al., 2007) , endocannabinoids in the nucleus accumbens shell may stimulate activation of orexinergic neurons (Kirkham et al., 2002; Zheng et al., 2003; Soria-Gómez et al., 2007) , and orexinergic projections to the nucleus accumbens shell (Mori et al., 2011) may cause a positive feedback cycle. The few studies performed suggested interactions between these systems, but the conclusions are not straightforward. Some of the problems arise from methodological obstacles, such as unreliable anti-orexin receptor antibodies (J. P. Kukkonen, unpublished data). In addition, the studies conducted were performed either with intact animals or with ex vivo slice preparations, where the neuronal circuitry involved may cause problems in identifying the actual sites of action of orexins and endocannabinoids.
In conclusion, the present study identified two enzyme cascades, cPLA 2 and DAGL, as potent orexin receptor targets and as the enzymes entirely responsible for the previously reported orexin-induced 3 H overflow from [ 3 H]AA-labeled cells (Turunen et al., 2010a) . The activation mechanisms for either enzyme species remain unclear. Each enzyme activity produces a signal of its own. Although cPLA 2 appears essential for the receptor-operated Ca 2ϩ influx, DAGL produces 2-AG, which is able to activate CB 1 cannabinoid receptors in a paracrine manner. This indicates that the suggested interactions between orexinergic and cannabinoidergic systems in the brain may take place through paracrine endocannabinoid signaling and that regulation of the some of the same physiological responses in appetite, for example, may take place through an arrangement such as this. Orexin receptors were suggested previously to heterodimerize with CB 1 receptors in heterologous coexpression systems (Hilairet et al., 2003; Ellis et al., 2006; Ward et al., 2011) . Our view is that interactions (alternatively or additionally) take place through 2-AG production, which represents a much more flexible signal system that does not require any molecular interactions between orexin and endocannabinoid receptors.
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